Hugel, a global total medical aesthetic company, announced on the 17th that it had obtained item permission for the HA filler Revolax from the Thai Food and Drug Administration (TFDA) on the 27th local time. Thailand is the largest beauty/plastic surgery market in Southeast Asia, and according to Decision Resource Group, a global market research firm, HA fillers are expected to grow rapidly at an annual average of 8% from 95 billion won in 2023 to 110 billion won in 2025. With the approval of this item, Hugel has succeeded in entering Thailand's HA filler/botulinum toxin/PDO suture market for the first time in Korea. Aestox, a botulinum toxin product, maintains the top spot in the industry with a market share of aroun